Phosphorex Appoints Jerry Williamson as Chief Executive Officer
HOPKINTON, Mass., Sept. 19, 2022 /PRNewswire/ — Followi capital investment from Ampersand Capital Partners, Phosphorex, a drug contract developm e nt and manufacturing organization (“CDMO”) providin polymer / lipid nanoparticles , announced today the appointment of Jarl Executive Officer.
Aug 13, 2025
Phosphorex, NOF CORPORATION, NeoSome Life Sciences, NanoImaging Services, and Envol Biomedical Unite to Form the LNP Alliance—Accelerating Lipid Nanoparticle Drug Development
Hopkinton, MA – May 8, 2025 – In a groundbreaking collaboration, Phosphorex, NOF CORPORATION, NeoSome Life Sciences, NanoImaging Services (NIS), and Envol Biomedical have joined forces to establish the LNP Alliance, a strategic partnership dedicated to advancing lipid nanoparticle (LNP) technology and accelerating the development of next-generation therapeutics.
May 8, 2025
Phosphorex Welcomes NOF CORPORATION as Shareholder and Strategic Partner
Hopkinton, MA and Tokyo – August 9, 2024– Phosphorex, a drug delivery-focused contract development and manufacturing organization (“CDMO”) backed by Boston-based private equity firm Ampersand Capital Partners, announced today that NOF CORPORATION has completed a strategic investment into the company.
Aug 9, 2024
Phosphorex and NOF CORPORATION Collaborate to Supply Lipid Nanoparticle Formulations using NOF's Proprietary Ionizable Lipid, COATSOME® SS Series
HOPKINTON, Mass. and TOKYO, April 30, 2024 /PRNewswire/ -- Phosphorex, an Ampersand Capital Partners company and drug delivery-focused contract development and manufacturing organization (“CDMO”), announced today a collaboration with NOF CORPORATION to supply its global clients with NOF’s COATSOME® SS Series proprietary ionizable lipids, further enhancing its leading position in providing lipid nanoparticle (LNP)-based drug delivery solutions to the market.
Apr 30, 2024